申联生物: 关于参股公司UB-221创新药II期临床研究进展的自愿性披露公告

Group 1 - The company has received an update on the progress of the innovative drug UB-221's Phase II clinical research from its associate company, Yangzhou Shizhi Source Biotechnology Co., Ltd. [1] - UB-221 is a humanized monoclonal antibody developed by the inventor of the anti-IgE therapy, Dr. Zhang Ziwen, and is designed to treat allergic reactions by neutralizing free IgE and inhibiting its synthesis [2][1]. - The ongoing Phase II clinical trial is a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of UB-221 in patients with chronic spontaneous urticaria (CSU), with a target enrollment of 144 patients, ultimately recruiting 145 [2]. Group 2 - The company is focused on building a world-class high-tech biopharmaceutical company and is actively expanding its business into the human innovative drug sector, leveraging its diverse biopharmaceutical technology platforms and talent reserves [3]. - The company is advancing the development of three innovative drugs: UB-221, UB-421, and UB-621, while also exploring new indications, supported by its technological expertise in synthetic peptides, genetic engineering, and mRNA [3].